


Press release

Merger & Acquisition

30th of September, 2022



Larka provided **Albumedix with
a **Vendor Due Diligence** to
support its **Sale Process**,
Acquired by **Sartorius**.**


Albumedix™

SARTORIUS

Advised by **Larka**

Larka is delighted to announce it acted as the sell-side **Vendor Commercial Due Diligence** provider to support the sale process of **Albumedix** – a leading recombinant albumin-based solution provider based in Nottingham, UK – acquired by the **Sartorius Group**.

Life science group Sartorius – through its French listed subgroup Sartorius Stedim Biotech – has reached an agreement to acquire all outstanding shares in Albumedix Ltd. from private investors, at an agreed purchase price of approximately £ 415Mn. Already established as a global leader in laboratory and bioprocessing technologies for the biopharmaceutical industry, Sartorius' objective with this acquisition is to further strengthen its portfolio of innovative advanced therapy solutions.

How Did Larka Support Albumedix' Sale Process?



This Vendor Commercial Due Diligence (VCDD) provided Albumedix with a high standard, data-driven and unbiased story of their company – meant to showcase the true value of the UK-based player to potential investors.

Larka's healthcare expertise and data were leveraged to provide Sartorius with an accurate picture of the recombinant human albumin (rHA) market size and dynamics for each modalities, including:

- Recombinant Protein
- Cell Therapy
- Gene Therapy
- Cell & Gene Therapy
- Attenuated, Inactivated and Oncolytic Viruses
- Invasive Medical Devices
- In Vitro Diagnostics (IVD)

The Larka M&A team provided a bottom-up analysis of the non-therapeutic human albumin market, covering all major application areas and therapeutic modalities. Through a rigorous market and industry engagement process, Larka were able to complete a comprehensive analysis, not shying away from difficult assumptions necessary, effectively translating the vast yet at times unpredictable market potential for recombinant human albumin based solutions.

Jonas S. Møller
Chief Executive Officer – Albumedix

Contact Us

Pierre-Anthony Brioir

Senior Director
+33 650 630 286
pabrioir@larka.com

Adrien Chalmont

Senior Manager
+33 621 006 115
achalmont@larka.com

Discover Related Services

Commercial Due Diligence

[Visit website](#) ►

Integrated Due Diligence

[Visit website](#) ►

Operational Due Diligence

[Visit website](#) ►

Technical Due Diligence

[Visit website](#) ►

About Albumedix

Albumedix is a science-driven company and recognized leader of best-in-class albumin-enabled solutions. Established in the UK in 1984, with a mission to empower excellence, Albumedix has supported its life-science partners to deliver hundreds of million safe doses of clinical and marketed therapeutics, globally. Albumedix' solutions include the world's only USP-NF compliant recombinant human albumin (Recombumin®), client-centric development and compliance services and drug-enhancing technologies (Veltis®). By always striving for more and collaboratively challenging status quo, Albumedix enables the development and commercialisation of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.

For more information, please visit www.albumedix.com

About Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group's Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2021, the company earned sales revenue of some 3.45 billion euros. At the end of 2021, nearly 14,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

For more information, please visit www.sartorius.com

About Larka

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit www.larka.com



Larka